Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients

被引:48
|
作者
Farina, C
Vargas, V
Heydari, N
Kümpfel, T
Meinl, E
Hohlfeld, R
机构
[1] Max Planck Inst Neurobiol, Dept Neuroimmunol, D-82152 Martinsried, Germany
[2] Univ Munich, Inst Clin Neuroimmunol, D-81366 Munich, Germany
关键词
multiple sclerosis; auto immunity; TH2-lymphocytes;
D O I
10.1016/S0165-5728(01)00490-8
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We analysed the humoral immune response to glatiramer acetate (GA, Copaxone) in 20 multiple sclerosis patients treated with GA, 20 patients not treated with GA and 20 normal control subjects. Using an ELISA for detection of total GA-reactive immunoglobulins (all isotypes), all treated patients but also 3/20 untreated and 8/20 healthy subjects scored positive at 1:20 plasma dilutions. At higher dilutions, 5/20 treated patients and two healthy donors had relatively high levels of anti-GA antibodies. Isotype and IgG subclass analysis revealed that the two antibody-positive normal subjects had IgM and small titers of IgG1 or IgG2 antibodies. In contrast, 18 of 20 GA-treated patients, had low but significant titers of GA-reactive IgG4 antibodies. This finding is consistent with the previously described GA-mediated induction of T-helper 2 (TH2)-like regulatory T cells. (C) 2002 Elsevier Science B.V All tights reserved.
引用
收藏
页码:188 / 192
页数:5
相关论文
共 50 条
  • [21] Glatiramer acetate therapy for multiple sclerosis: a review
    Perumal, Jai
    Filippi, Massimo
    Ford, Corey
    Johnson, Kenneth
    Lisak, Robert
    Metz, Luanne
    Tselis, Alexandros
    Tullman, Mark
    Khan, Omar
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2006, 2 (06) : 1019 - 1029
  • [22] Effects of interferon and glatiramer acetate on cytokine patterns in multiple sclerosis patients
    Ganji, Ali
    Monfared, Mohsen Ebrahimi
    Shapoori, Shima
    Nourbakhsh, Parisa
    Ghazavi, Ali
    Ghasami, Keyvan
    Mosayebi, Ghasem
    CYTOKINE, 2020, 126
  • [23] Glatiramer in the treatment of multiple sclerosis
    Rizvi, Syed A.
    Kim, Edward
    Moodie, Jennifer
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2006, 1 (03) : 283 - 289
  • [24] Development of myasthenia gravis in a patient with multiple sclerosis during treatment with glatiramer acetate
    Achim Frese
    Florian Bethke
    Peter Lüdemann
    Florian Stögbauer
    Journal of Neurology, 2000, 247 : 713 - 713
  • [25] A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis
    Zhang, JW
    Hutton, G
    Zang, Y
    CLINICAL THERAPEUTICS, 2002, 24 (12) : 1998 - 2021
  • [26] Glatiramer acetate in situ forming gel, a new approach for multiple sclerosis treatment
    Shobeirean, Anahita
    Attar, Hossein
    Varshochian, Reyhaneh
    Rezvanfar, Mohammad Amin
    DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 32 (02) : 649 - 664
  • [27] Erythema nodosum and glatiramer acetate treatment in relapsing-remitting multiple sclerosis
    Thouvenot, E.
    Hillaire-Buys, D.
    Bos-Thompson, M. A.
    Rigau, V.
    Durand, L.
    Guillot, B.
    Camu, W.
    MULTIPLE SCLEROSIS JOURNAL, 2007, 13 (07) : 941 - 944
  • [28] Development of myasthenia gravis in a patient with multiple sclerosis during treatment with glatiramer acetate
    Frese, A
    Bethke, F
    Lüdemann, P
    Stögbauer, F
    JOURNAL OF NEUROLOGY, 2000, 247 (09) : 713 - 713
  • [29] Autoimmune hyperthyroidism in multiple sclerosis under treatment with glatiramer acetate -: a case report
    Heesen, C
    Gbadamosi, J
    Schoser, BGH
    Pöhlau, D
    EUROPEAN JOURNAL OF NEUROLOGY, 2001, 8 (02) : 199 - 199
  • [30] Factors related with treatment adherence to interferon β and glatiramer acetate therapy in multiple sclerosis
    Río, L
    Porcel, J
    Téllez, N
    Sánchez-Betancourt, A
    Tintoré, M
    Arévalo, MJ
    Nos, C
    Montalban, X
    MULTIPLE SCLEROSIS, 2005, 11 (03): : 306 - 309